Vitiligo Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Vitiligo pipeline constitutes 20+ key companies continuously working towards developing 20+ Vitiligo treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Vitiligo Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vitiligo Market.

Some of the key takeaways from the Vitiligo Pipeline Report: https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Vitiligo treatment therapies with a considerable amount of success over the years.
• Vitiligo companies working in the treatment market are Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others, are developing therapies for the Vitiligo treatment
• Emerging Vitiligo therapies in the different phases of clinical trials are- Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others are expected to have a significant impact on the Vitiligo market in the coming years.
• In March 2025, STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology firm focused on developing, commercializing, and marketing innovative dermatologic treatment products, announced the findings of a newly published study in Japan. The study further confirms the technological benefits of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology compared to other UVB light sources, which are less precise and lack the repetition rate and fluence capabilities of Excimer Light for treating conditions such as Vitiligo, Psoriasis, Alopecia Areata, and Atopic Dermatitis.
• In February 2025, Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company specializing in host-directed therapies for immuno-inflammatory diseases, today announced its financial results for the quarter ending December 31, 2024, along with a business update. During this period, the company made progress with its lead asset, EB06, an anti-CXCL10 monoclonal antibody candidate aimed at providing effective and lasting treatment for vitiligo.
• In January 2025, VYNE Therapeutics, a US-based pharmaceutical company, completed patient enrollment in its randomized Phase IIb clinical trial evaluating VYN201 gel (repibresib) for the treatment of non-segmental vitiligo. This double-blind, vehicle-controlled study is examining the safety, pharmacokinetics, and effectiveness of a once-daily application of the gel across three dosage groups-1%, 2%, and 3%-in comparison to a vehicle.
• In May 2024, Edesa Biotech, Inc. (NASDAQ: EDSA) is preparing to launch a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo in patients. Vitiligo is a condition where certain areas of the skin lose color, and non-segmental vitiligo is marked by patches on both sides of the body. This condition occurs when pigment-producing cells (melanocytes) either die or stop producing melanin, often due to autoimmune diseases, genetics, or a triggering event such as stress, sunburn, or skin trauma.

Vitiligo Overview
Vitiligo is a chronic skin condition where the skin loses its pigment (color) due to the destruction or malfunction of melanocytes - the cells responsible for producing melanin (skin pigment).
This leads to the development of white patches on various parts of the body, including the skin, hair, and sometimes even inside the mouth or eyes.

Get a Free Sample PDF Report to know more about Vitiligo Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Vitiligo Drugs Under Different Phases of Clinical Development Include:
• Phimelanotide: Clinuvel Pharmaceuticals
• BNZ-1: Bioniz Therapeutics
• TAGX-0003: TAGCyx Biotechnologies
• TT-01: Temprian Therapeutics
• ATI-1777: Aclaris Therapeutics
• AC-1101: TWi Biotechnology
• Cerdulatinib: Dermavant Science
• AMG 714: Amgen
• Ritlecitinib: Pfizer
• Ruxolitinib: Incyte Corporation
• Afamelanotide: Clinuvel Pharmaceuticals Limited
• Crisaborole 2% Topical Ointment: Pfizer

Vitiligo Route of Administration
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Vitiligo Molecule Type
Vitiligo Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Vitiligo Pipeline Therapeutics Assessment
• Vitiligo Assessment by Product Type
• Vitiligo By Stage and Product Type
• Vitiligo Assessment by Route of Administration
• Vitiligo By Stage and Route of Administration
• Vitiligo Assessment by Molecule Type
• Vitiligo by Stage and Molecule Type

DelveInsight's Vitiligo Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Vitiligo product details are provided in the report. Download the Vitiligo pipeline report to learn more about the emerging Vitiligo therapies
https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Vitiligo Therapeutics Market include:
Key companies developing therapies for Vitiligo are - Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, among others.

Vitiligo Pipeline Analysis:
The Vitiligo pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
• Vitiligo key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Vitiligo drugs and therapies
https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Vitiligo Pipeline Market Drivers
• Increasing awareness, demand of novel therapies, large patient pool and better healthcare infrastructure are some of the important factors that are fueling the Vitiligo Market.

Vitiligo Pipeline Market Barriers
• However, patient compliance, chronic nature of disease and long term therapy, lack of adequate financial assistance & stringent regulatory procedure and other factors are creating obstacles in the Vitiligo Market growth.

Scope of Vitiligo Pipeline Drug Insight
• Coverage: Global
• Key Vitiligo Companies: Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others
• Key Vitiligo Therapies: Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others
• Vitiligo Therapeutic Assessment: Vitiligo current marketed and Vitiligo emerging therapies
• Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.